Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Increases By 13.0%

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 20,000 shares, an increase of 13.0% from the October 15th total of 17,700 shares. Based on an average trading volume of 4,700 shares, the days-to-cover ratio is currently 4.3 days.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock traded up $0.00 during mid-day trading on Monday, reaching $0.19. 4,084 shares of the company’s stock traded hands, compared to its average volume of 17,280. The stock has a 50 day moving average of $0.21 and a two-hundred day moving average of $0.21. Jasper Therapeutics has a 12-month low of $0.04 and a 12-month high of $0.38.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.